OncoMatch/Clinical Trials/NCT06633341
Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-lymphoma
Is NCT06633341 recruiting? Yes, currently enrolling (Jun 2026). This Early Phase 1 trial studies CD5 CAR T-cells for t-lymphoblastic lymphoma.
Treatment: CD5 CAR T-cells — A Clinical Study on the Safety and Effectiveness of targeting CD5 CAR-T Cells in the treatment of r/r CD5+ T-lymphoma
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD5 overexpression (>90%)
CD5 expression rate was >90%
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: chemotherapy — second-line or later
Subjects did not go into remission or relapse after receiving second-line or more chemotherapy regiments
Must have received: autologous hematopoietic stem cell transplantation
Relapse after autologous hematopoietic stem cell transplantation
Cannot have received: gene therapy
Before using any gene therapy products
Lab requirements
Kidney function
creatinine ≤176.8 (mol/L)
Liver function
Total bilirubin ≤51 (mol/L), ALT/AST ≤ 3x ULN
Cardiac function
LVEF ≥50%
Total bilirubin ≤51 (mol/L), Alanine aminotransferase (ALT)/Aspartate aminotransferase (AST) ≤ 3 times the upper limit of the normal range, creatinine ≤176.8 (mol/L); Echocardiography showed left ventricular ejection fraction (LVEF) ≥50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06633341 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior gene therapy disqualifies patients from enrollment.
Does this trial require CD5?
Yes, CD5 overexpression is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify